TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW
PRESS RELEASES

Y-mAbs Announces Sale Of Priority Review Voucher

  • By GlobeNewswire
  • Dec 28, 2020 9:00 AM EST
PRESS RELEASES

Y-mAbs Announces Pipeline Update

  • By GlobeNewswire
  • Dec 16, 2020 9:00 AM EST
PRESS RELEASES

Y-mAbs Announces Update On DANYELZA® (naxitamab-gqgk) At ESMO

  • By GlobeNewswire
  • Dec 9, 2020 9:00 AM EST
PRESS RELEASES

FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) For The Treatment Of Neuroblastoma

  • By GlobeNewswire
  • Nov 25, 2020 5:02 PM EST
PRESS RELEASES

Y-mAbs Announces Update On Omburtamab In DIPG

  • By GlobeNewswire
  • Nov 19, 2020 9:00 AM EST
PRESS RELEASES

Y-mAbs Announces FDA Clearance Of IND For Lutetium-177 Labeled Omburtamab Antibody For Adult Indications

  • By GlobeNewswire
  • Oct 26, 2020 9:10 AM EDT
PRESS RELEASES

Y-mAbs Announces Update On Naxitamab And Omburtamab In Neuroblastoma

  • By GlobeNewswire
  • Oct 16, 2020 9:00 AM EDT
PRESS RELEASES

Y-mAbs Announces FDA Clearance Of IND For Its Lutetium-177 Labeled Omburtamab Antibody

  • By GlobeNewswire
  • Oct 14, 2020 9:00 AM EDT
PRESS RELEASES

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Y-mAbs Therapeutics, Inc. - YMAB

  • By PR Newswire
  • Oct 8, 2020 6:13 PM EDT
PRESS RELEASES

Y-mAbs' Nivatrotamab For The Treatment Of Patients With Neuroblastoma Granted Orphan Drug Designation And Rare Pediatric Disease Designation By FDA

  • By GlobeNewswire
  • Oct 7, 2020 9:00 AM EDT
PRESS RELEASES

Y-mAbs Provides Regulatory Update On Omburtamab For The Treatment Of Patients With Neuroblastoma

  • By GlobeNewswire
  • Oct 5, 2020 4:01 PM EDT
PRESS RELEASES

Y-mAbs Announces Completion Of Submission Of Omburtamab Biologics License Application To FDA

  • By GlobeNewswire
  • Aug 6, 2020 9:00 AM EDT
PRESS RELEASES

Y-mAbs Announces Data To Be Presented At 2020 SIOP

  • By GlobeNewswire
  • Jul 27, 2020 4:01 PM EDT
PRESS RELEASES

Y-mAbs Announces Update On SADA Technology And New Preclinical SADA Construct

  • By GlobeNewswire
  • Jul 14, 2020 9:00 AM EDT
PRESS RELEASES

Y-mAbs Announces Initiation Of Submission Of Omburtamab Rolling Biologics License Application To The FDA

  • By GlobeNewswire
  • Jun 30, 2020 4:01 PM EDT
PRESS RELEASES

Y-mAbs Announces U.S. FDA Acceptance Of Biologics License Application For Danyelza™ (naxitamab) For The Treatment Of Neuroblastoma For Priority Review

  • By GlobeNewswire
  • Jun 2, 2020 9:00 AM EDT
PRESS RELEASES

Y-mAbs Announces Data To Be Presented At 2020 ASCO Annual Meeting

  • By GlobeNewswire
  • May 13, 2020 9:00 AM EDT
PRESS RELEASES

Y-mAbs Announces Appointment Of Laura J. Hamill To Its Board Of Directors

  • By GlobeNewswire
  • Apr 24, 2020 9:00 AM EDT
PRESS RELEASES

Y-mAbs Announces Submission Of Naxitamab Biologics License Application To U.S. FDA

  • By GlobeNewswire
  • Apr 1, 2020 9:00 AM EDT
PRESS RELEASES

Y-mAbs To Announce 2019 Financial And Operating Results On March 12, 2020

  • By GlobeNewswire
  • Mar 5, 2020 9:00 AM EST
PRESS RELEASES

Y-mAbs Announces Positive Pre-BLA Meeting With FDA For Omburtamab

  • By GlobeNewswire
  • Feb 26, 2020 4:01 PM EST
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.